This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

IsoRay Ships First GliaSite® Brain Cancer Treatment

IsoRay, Inc. (Amex: ISR) announced today it has shipped its first GliaSite® radiation therapy system. The Company initiated sales after receiving final approval this week from the State of Washington Department of Health to manufacture its GliaSite® radiation therapy system. The GliaSite® radiation therapy system is a balloon catheter device used in the treatment of brain cancer. Having already received FDA clearance, the Washington State regulatory approval opened the door for sales of IsoRay's GliaSite® brain cancer treatment in the United States.

IsoRay CEO Dwight Babcock says inquiries are on the rise, "News of final regulatory approval has generated a great deal of interest throughout the medical community in the U.S. and internationally. We are hearing from physicians as well as brain cancer patients who are seeking treatment options for Glioblastomas and metastasized brain cancers. "

The GliaSite® radiation system offers an innovative alternative that presents an important advance over previous brain cancer treatments. Doctors are able to use the system to directly place a specified dosage of liquid radiation in areas where cancer is most likely to still remain after completion of brain tumor removal. The ability to precisely place a specified dosage of this form of radiation means there is less likelihood for damage to occur to healthy brain tissue compared to other alternative treatments. Importantly, the GliaSite® radiation treatment diminishes the ability of the tumor to recur which means important benefits for patients in longevity as well as quality of life.

The news comes as the Company is moving forward to achieve FDA clearance of liquid Cesium-131 for use with the GliaSite® radiation system. IsoRay is the exclusive manufacturer of Cesium-131 for cancer treatment. In its current form, the pioneering brachytherapy treatment represents one of the most important advancements in internal radiation therapy in 20 years. In other developments, CEO Babcock revealed that discussions are already underway regarding the application of Cesium-131 for treating cancers in other body sites including breast and esophageal cancers.

Babcock says he views the latest developments as just the beginning of important benefits from GliaSite® for the company, too. "We expect GliaSite® to be a tremendous revenue generator. It is my sense that it will fuel other important opportunities for IsoRay's growth and expansion."

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,039.49 +60.36 0.36%
S&P 500 1,992.37 +5.86 0.30%
NASDAQ 4,532.1040 +5.6220 0.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs